Brii Biosciences Limited
BRIBF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $49,936 | $617 | $51,626 | $92,542 |
| % Growth | 7,993.4% | -98.8% | -44.2% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $49,936 | $617 | $51,626 | $92,542 |
| % Margin | 100% | 100% | 100% | 100% |
| R&D Expenses | $249,847 | $402,705 | $440,634 | $494,615 |
| G&A Expenses | $153,155 | $55,685 | $53,465 | $79,307 |
| SG&A Expenses | $203,943 | $57,104 | $80,326 | $79,307 |
| Sales & Mktg Exp. | $50,788 | $1,419 | $26,861 | $0 |
| Other Operating Expenses | $0 | $85,540 | $44,854 | $129,097 |
| Operating Expenses | $453,790 | $545,349 | $565,814 | $703,019 |
| Operating Income | -$403,854 | -$544,301 | -$513,845 | -$610,477 |
| % Margin | -808.7% | -88,217.3% | -995.3% | -659.7% |
| Other Income/Exp. Net | -$108,527 | $359,931 | $24,064 | -$3,580,607 |
| Pre-Tax Income | -$512,381 | -$184,370 | -$489,781 | -$4,191,084 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$508,162 | -$174,829 | -$484,312 | -$4,120,229 |
| % Margin | -1,017.6% | -28,335.3% | -938.1% | -4,452.3% |
| EPS | -0.7 | -0.24 | -0.67 | -9.48 |
| % Growth | -191.7% | 64.2% | 92.9% | – |
| EPS Diluted | -0.7 | -0.24 | -0.67 | -9.48 |
| Weighted Avg Shares Out | 730,247 | 728,102 | 723,478 | 439,047 |
| Weighted Avg Shares Out Dil | 730,246 | 728,100 | 723,478 | 439,047 |
| Supplemental Information | – | – | – | – |
| Interest Income | $84,788 | $108,023 | $37,204 | $6,490 |
| Interest Expense | $0 | $494 | $851 | $1,175 |
| Depreciation & Amortization | $2,245 | $15,674 | $7,944 | $7,678 |
| EBITDA | -$401,609 | -$168,202 | -$503,584 | -$602,799 |
| % Margin | -804.2% | -27,261.3% | -975.4% | -651.4% |